IGI Logo

Zydus Lifesciences gains on getting USFDA’s final approval for Scopolamine Transdermal System

Aug-30-2024   14:08 Hrs IST

Zydus Lifesciences is currently trading at Rs. 1145.55, up by 13.30 points or 1.17% from its previous closing of Rs. 1132.25 on the BSE.

The scrip opened at Rs. 1140.00 and has touched a high and low of Rs. 1159.00 and Rs. 1128.95 respectively. So far 155881 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023.

Last one week high and low of the scrip stood at Rs. 1159.00 and Rs. 1105.30 respectively. The current market cap of the company is Rs. 114740.86 crore.

The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.22% and 6.79% respectively.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Scopolamine Transdermal System 1 mg/3 days. (USRLD: Transderm Scop Transdermal System 1 mg/3 days). This is the fifth ANDA approval for the company in the transdermal portfolio, leveraging the group’s strengths in the manufacturing of complex drug device dosage forms. 

Scopolamine Transdermal System is indicated to prevent nausea and vomiting after anaesthesia, narcotic pain medicines, and surgery. It is also used to prevent nausea and vomiting caused by motion sickness. The Scopolamine Transdermal System will be produced at the group’s transdermal manufacturing site at SEZ, Matoda, Ahmedabad. 

Scopolamine Transdermal System 1 mg/3 days had annual sales of $69.6 million in the United States (IQVIA MAT June 2024). The group now has 400 approvals and has so far filed over 465 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.